|Bid||5.90 x 2200|
|Ask||6.04 x 1100|
|Day's range||5.84 - 6.27|
|52-week range||3.28 - 8.87|
|Beta (5Y monthly)||0.20|
|PE ratio (TTM)||N/A|
|Earnings date||20 Feb 2023 - 24 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||11.60|
Long term investing works well, but it doesn't always work for each individual stock. We really hate to see fellow...
NASCAR Champion Brad Keselowski to Run No. 6 NEXLIZET (bempedoic acid and ezetimibe) Ford in Famed Daytona 500CONCORD, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- RFK Racing has announced that Esperion Therapeutics, a Michigan-based pharmaceutical company, has partnered with the team for a multi-year agreement pursuant to which Esperion will promote two cholesterol lowering treatments – NEXLIZET (bempedoic acid and ezetimibe) and NEXLETOL (bempedoic acid). NEXLIZET will be featured on Keselowski’s N
PTC Therapeutics (PTCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.